Published on Friday, October 29, 2010 FDA said in briefing documents posted ahead of the Vaccines and Related Biological Products Advisory Committee meeting on Nov. 17 that data support approval of Gardasil HPV vaccine from Merck & Co. Inc. (NYSE:MRK) to prevent anal intraepithelial neoplasia (AIN) and anal cancer caused by HPV types 6, […]
American Association for Cancer Research
Francesca M. Carozzi1, Maria L. Tornesello2, Elena Burroni1, Giovanna Loquercio2, Giuseppe Carillo3, Claudio Angeloni4, Aurora Scalisi5, Rosalba Macis6, Francesco Chini7, Franco M. Buonaguro2, Paolo Giorgi Rossi7 and for the HPV Prevalence Italian Working Group
Paolo Giorgi Rossi, Laziosanità, Via di Santa Costanza, 53, Rome 00198, Italy. E-mail: firstname.lastname@example.org
Background: The aim of this multicentric study was to identify human papillomavirus (HPV) type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia 2/3 (CIN2/3) in Italy.
Methods: Cases were sampled through the electronic databases at the pathology units of eight centers in six regions from central and southern Italy. HPV types were detected from paraffin-embedded tissue samples and cervical specimens through amplification of HPV DNA with GP5+/GP6+ primers, followed by genotyping with reverse line blot (RLB). Untyped HPV-positive samples were sequenced. HPV-negative samples underwent nested PCR, followed by either RLB or sequencing. Finally, the remaining HPV-negative samples were amplified with primers targeting the virus E6 to E7 regions.